Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow VERTEX PHARMACEUTICALS INC / MA

Get SEC filing alerts via email and in your feed for VERTEX PHARMACEUTICALS INC / MA

VRTX

VERTEX PHARMACEUTICALS INC / MA

About VERTEX PHARMACEUTICALS INC / MA

Vertex Pharmaceuticals is a global biotech company focused on developing transformative medicines for serious diseases, primarily in cystic fibrosis, blood disorders, and pain. Its core portfolio includes approved therapies targeting CFTR mutations, gene-editing treatments for sickle cell disease and thalassemia, and novel pain inhibitors. The company emphasizes innovative research, gene and cell therapies, strategic collaborations, and expanding access worldwide to improve patient outcomes.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from VERTEX PHARMACEUTICALS INC / MA

1
1
VERTEX PHARMACEUTICALS INC / MA Vertex Pharmaceuticals Reports 8% Revenue Growth to $2.99 Billion in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
VERTEX PHARMACEUTICALS INC / MA Vertex Pharmaceuticals Reports $12.0 Billion Revenue and $3.95 Billion Net Income for Fiscal Year 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
VERTEX PHARMACEUTICALS INC / MA Vertex Pharmaceuticals Reports $3.1 Billion Revenue in Q3 2025, Driven by Cystic Fibrosis Treatment

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
VERTEX PHARMACEUTICALS INC / MA Vertex Pharmaceuticals Reports $2.964 Billion Revenue and $1.033 Billion Net Income in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
VERTEX PHARMACEUTICALS INC / MA Vertex Pharmaceuticals Reports $2.77 Billion Revenue, Net Income Declines 41%

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
VERTEX PHARMACEUTICALS INC / MA Vertex Pharmaceuticals Reports 12% Revenue Growth, Net Loss in Q3 2024 Due to Increased Expenses and Strategic Acquisitions

Via official filing (AI summary) | over 1 year ago | 0 comments